Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:52:57.869Z.
Consensus retrieved: 2026-10-06T17:12:26.977Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:52:57.869Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 667dd3b64d3a271f66e92979ae52668ccbc7e2b5b2cdee7c8377401ac3ef4785
Forward PE Ratio (N/A) = Dated Quote Price ($22.41) / Consensus Forward EPS ($-5.09)
FORWARD PE RATIO
N/A
Tectonic Therapeutic, Inc.
Market Cap
$422.86M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $422.86M | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | N/A |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 90.32 |
| Prothena Corporation plc (PRTA)vs › | $419.87M | 72.91 |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | N/A |
| Rezolute, Inc. (RZLT)vs › | $415.98M | N/A |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $22.41, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-5.09 | $-5.27 – $-4.93 | 7 | n/m |
| 2027-12-31 | $-5.38 | $-6.19 – $-3.72 | 7 | n/m |
| 2028-12-31 | $-6.01 | $-7.69 – $-2.42 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
